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abstract: Non-tubal ectopic pregnancies are a rare subgroup of ectopic pregnancies implanted at sites other than the Fallopian tube. Mor-
tality fromnon-tubal ectopic pregnancies is higher comparedwith that for tubal ectopic pregnancies, and theyarebecomingmore common, partly
due to the rising incidence of Caesarean sections and use of assisted reproductive technologies. Non-tubal ectopic pregnancies can be especially
difﬁcult to treat. Surgical treatment is complex, and follow-up after medical treatment is usually protracted. There is therefore a need for more
effectivemedical therapies to resolvenon-tubal ectopic pregnancies and reduceoperative intervention.Wehave recently reported successful use
of combination geﬁtinib (an orally available epidermal growth factor receptor inhibitor) andmethotrexate for treatment of tubal pregnancies. To
our knowledge, this combination has not been used to treat non-tubal pregnancies. Herewe report the use of combination geﬁtinib andmetho-
trexate to treat eight women with stable, non-tubal ectopic pregnancies at two tertiary academic teaching hospitals (Edinburgh, UK and
Melbourne, Australia); ﬁve interstitial and three Caesarean section scar ectopic pregnancies. Pretreatment serum hCG levels ranged from
2458 to 48 550 IU/l, and six women had pretreatment hCG levels .5000 IU/l. The women were co-administered 1–2 doses of i.m. metho-
trexate (50 mg/m2 onDay 1,+ Day 4 or Day 7) with seven once daily doses of oral geﬁtinib (250 mg). Thewomenweremonitored until com-
plete resolution of the ectopic pregnancy, deﬁned as a serum hCG,15 IU/l. Time to resolution (days from ﬁrst methotrexate dose until serum
hCG,15 IU/l), safety and tolerability, complication rates and subsequent fertility outcomeswere also recorded.All eightwomenwere success-
fully treated with combination geﬁtinib and methotrexate. The most common side effects were transient acne/rash and diarrhoea, known side
effects of geﬁtinib. All women promptly resumedmenstruation and importantly, threewomen subsequently conceived spontaneously. Twohave
delivered a healthy infant at term and the third is currently in her second trimester of pregnancy. Hence, our case series supports a future clinical
trial to determine the efﬁcacy of combination geﬁtinib and methotrexate to treat non-tubal ectopic pregnancies.
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Introduction
Ectopic pregnancies (EPs) have an incidence of 1–2% of all pregnan-
cies. They occur when a fertilized ovum implants away from the endo-
metrial cavity, most commonly (.95%) in one of the Fallopian tubes
(Jurkovic andWilkinson, 2011; Fylstra, 2012). EPs can, however, implant
inmore unusual locations such aswithin aCaesarean section scar, within
the interstitial portion of the Fallopian tubes, in the cervix, on the ovary
and potentially anywhere in the abdominal cavity. Mortality from non-
tubal ectopic pregnancies is higher than ectopic pregnancies generally,
and theyarebecomingmorecommondue to assisted reproductive tech-
nologies, and possibly due to increasing Caesarean section rates (Chetty
and Elson, 2009; Verma et al., 2011). Non-tubal ectopic pregnancies are
generally difﬁcult to treat and often require a combination of surgical and
medical methods.
The literature around management of non-tubal EPs is limited to
case reports and series, describing a range of minimally invasive surgical,
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radiological and medical interventions including laparoscopic and hys-
teroscopic resection, uterine artery embolization, ultrasound guided
injections of the gestational sac with potassium chloride and/or metho-
trexate, and systemic treatment with drugs such as methotrexate, mife-
pristone and misoprostil (Verma et al., 2011; Fylstra, 2012). Treatment
choice depends on the site, size and pretreatment serum hCG level of
the non-tubal EP. In particular, interstitial, Caesarean section scar and
cervical EPs often still require surgical resection and/or instrumentation
of the uterus,with potential risks to thewoman’s subsequent reproduct-
ive capacity. Because of their rarity as a clinical entity, the best manage-
ment of non-tubal EPs has been difﬁcult to establish.
In preclinical studies and a phase I single arm, open label study, we
demonstrated that co-administering geﬁtinib (an epidermal growth factor
receptor inhibitor) with methotrexate to treat ectopic pregnancies
appeared safe. Furthermore, we obtained preliminary data suggesting this
combination may have a time to resolution which is 34% faster compared
with treatmentusingmethotrexatealone (Nilssonetal., 2013;Skubiszetal.,
2013). This suggested adding geﬁtinib to methotrexatemay improve on its
efﬁcacy in medically resolving ectopic pregnancies. We therefore won-
dered whether this combination could be potentially used to treat non-
tubal ectopic pregnancies more effectively. Here we report a case series
of eightwomenwithnon-tubal EPs treatedwith geﬁtinib andmethotrexate.
Methods
Institutional human research ethics approval was sought and obtained at both
participating sites (Southern Health Human Research Ethics Committee B,
11180B, andScotlandAResearchEthicsCommittee, 11/AL/0350) toallowad-
ministration of combination geﬁtinib and methotrexate to eight women with
non-tubal EPs, and written informed consent was obtained from each partici-
pant. The diagnosis of non-tubal EP wasmade according to set ultrasound diag-
nostic criteria (Jurkovic et al., 2003; Jurkovic, 2007) in combination with
quantitative serum hCG measurement. Inclusion criteria required the women
to be assessed as haemodynamically stable (with no pallor, postural change in
blood pressure, syncope or pre-syncope, severe abdominal pain or signs of ab-
dominal peritonism, aswell as requiring anormal serumhaemoglobin andhaem-
atocrit) and to have normal baseline white cell count, renal and hepatic indices.
Exclusioncriteria includedseveredermatological, gastrointestinalandpulmonary
comorbidities (systems most likely to be affected by combination treatment),
allergy to geﬁtinib and/or methotrexate and Japanese ethnicity (the latter
being an increased risk factor for geﬁtinib-associated interstitial lung disease).
Participants were treated with daily oral geﬁtinib 250 mg for 7 days in add-
ition to 50 mg/m2 of i.m. methotrexate on Day 1. Quantitative serum hCG
measurement was repeated on Day 4 and Day 7 of treatment, and initial
treatment success was deﬁned as a ≥15% fall in serum hCG between
these two measurements. Additional doses of methotrexate at 50 mg/m2
were administered where this did not occur, or where therewas a signiﬁcant
rise in the serum hCGbetweenDay 1 andDay 4. Serum hCGwas thenmea-
sured weekly until there was complete resolution of the EP, deﬁned as a
serum hCG of ≤15 IU/l. Haematological, renal and hepatic blood indices
were monitored at each visit.
Treatment outcome parameters recorded included time to resolution
(days from ﬁrst methotrexate dose until serum hCG ,15 IU/l), safety,
tolerability and complication rates. Side effects and symptomswere classiﬁed
according to the Common Terminology and Criteria for Adverse Events
(CTCAE) version 4.03 (National Cancer Institute, National Institutes of
Health, U.S.Department ofHealth andHuman Services, June 14, 2010). Par-
ticipants were contacted at 3, 6 and 12months post-treatment to document
return of menstrual cycles and any subsequent fertility outcomes.
Results
We recruited eight women with stable non-tubal EPs: ﬁve women with
interstitial EPs and three women with Caesarean section scar EPs. The
range of pretreatment serum hCG levels of participants was between
2458 and 48550 IU/l.
All women were successfully treated with combination geﬁtinib and
methotrexate—none of the women required surgical and/or invasive
intervention to achieve cure and furthermore, none of the participants
experienced blood loss requiring transfusion. A second dose of i.m.
methotrexate was administered to 5/8 of participants, in 3/5 participants
becauseofasigniﬁcantrise inserumhCGbetweenDays1and4of treatment
and in the remaining 2/5, because the serum hCG had not fallen ≤15%
between Days 4 and 7 of treatment. Duration of follow-up ranged
from25 to196days.Table I summarizes thenon-tubal pregnancy character-
istics, treatment and outcomes of each participant. Supplementary Table I
.............................................................................................................................................................................................
Table I Participant ectopic pregnancy (EP) and treatment details.
Participant EP type Day 1 hCG
(IU/l)
Day 4 hCG
(IU/l)
Day 7 hCG
(IU/l)
Fetal heart on
ultrasound?
2nd dose of
MTX given?
Time to
resolutiona (days)
1 Interstitial 2458 2049 2350 No Yes (Day 7) 31
2 Interstitial 6528 6163 6502 Yes Yes (Day 7) 38
3 Caesarean
scar
8716 13 836 9906 No Yes (Day 4) 48
4 Interstitial 8575 6125 4810 No No 67
5 Caesarean
scar
48 558 54 747 47 551 Yes Yes (Day 4) 196
6 Interstitial 9730 11 966 12 484 No Yes (Day 4) 63
7 Interstitial 2649 3662 3497 No No 25
8 Caesarean
scar
8707 5981 3041 No No 53
MTX, methotrexate.
aResolution deﬁned as serum hCG ,15 IU/l.
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provides participant baseline demographic data and additional
ultrasound characteristics of the non-tubal pregnancies.
The hCG courses of the ﬁve interstitial EPs were quite varied (Fig. 1).
Two participants demonstrated an adequate fall in hCG between Day 4
andDay 7 (participants 4 and 7; see Table I). Participants 1 and 2 experi-
enced an initial fall in serum hCGbetweenDay 1 andDay 4, but this curi-
ously rose to pretreatment levels atDay7 in both cases. Thiswas despite
ultrasound evidence of treatment efﬁcacy in participant 2, where a fetal
heart seen pretreatment was not detected on re-scanning at Day 4. In
contrast, the hCG courses of the Caesarean section scar EPs all demon-
strated a fall in hCG between Days 4 and 7 of treatment, including one
with an extremely high pretreatment hCG level of 48 558 IU/l and a
fetal heart seen on ultrasound prior to treatment.
The combination of oral geﬁtinib and systemic methotrexate was well
tolerated. Themost commonly reported adverse events were a papulo-
pustular rash (Fig. 2), diarrhoea and dizziness, consistent with the known
side effect proﬁle of geﬁtinib. All adverse events were classiﬁed as either
grade 1 (mild) or grade 2 (moderate) according to the CTCAE, and all
women were able to continue with employment and/or family respon-
sibilities after discharge from hospital and during follow-up. All reported
adverse events resolved spontaneously after completion of treatment,
with only occasional symptomatic treatment required. Importantly,
there were no complications of treatment and in particular, none of
the participants experienced haemorrhage requiring blood transfusion.
All participants promptly resumed their menstrual cycles (i.e. within 6
weeks of cure), and 3/8 so far have achieved a subsequent spontaneous
intrauterine pregnancy. Two of these pregnancies have resulted in the
successful births of a healthy infant at term, with a third woman in the
second trimester of an uncomplicated pregnancy.
Discussion
The results of this case series suggest that combination geﬁtinib and
methotrexate therapy could be a safe and effective treatment for non-
Figure1 The serumhCGcourses of participants. Interstitial ectopic pregnancies shown in blue andCaesarean section scarectopic pregnancies shown in
red. Serum hCGs were measured on Days 4, 7 and 11 of treatment and weekly thereafter until resolution (hCG,15 IU/l), with the protocol commencing
again after a repeat dose of methotrexate on Day 4 or Day 7 in 5/8 participants. Numbers on the diagonal correlate to the participant and arrows indicate
additional doses of methotrexate.
Figure 2 An example of the papulopustular (acneiform) rash experi-
enced by some participants in response to treatment with oral geﬁtinib.
The rash is most prominent in areas exposed to UV light, i.e. the face,
neck and de´colletage.
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tubal ectopic pregnancies. The combination treatment was successful in
resolving the pregnancies without recourse to surgery or more invasive
medical treatments in all cases. Six of the eight women had serum hCG
levels of .5000 IU/l, levels where previous studies would suggest the
single-dose methotrexate protocol (which includes a second dose if
required) may be less effective (Menon et al., 2007).
Non-tubal EPs are uncommon, and consequently, their optimal man-
agement has not been ﬁrmly established. Additionally, each type of non-
tubal EP presents different management challenges (Chetty and Elson,
2009). Advances in ultrasound have enabled earlier and more accurate
diagnosis, and the use of minimally invasive techniques has signiﬁcantly
improved the outcomes of women diagnosed with non-tubal EPs
(Chetty and Elson, 2009). Nevertheless, non-invasive management
remains key to minimizing any risk to subsequent pregnancies.
Non-invasive treatment of non-tubal and indeed all EPs is almost
exclusively limited to systemic methotrexate (Hajenius et al., 2000).
The effectiveness of methotrexate in the treatment of EP is limited by
the pretreatment serum hCG, with ectopic pregnancies with levels
.5000 IU/l signiﬁcantly less likely to be treated successfully (Menon
et al., 2007). Because of difﬁculty accurately characterizing their location
with ultrasound, non-tubal EPs are still diagnosed at more advanced
gestations with higher pretreatment serum hCG levels, thus limiting
the usefulness of this non-invasive approach (Chetty and Elson, 2009).
Wehavedemonstrated effectivemanagement ofwomenwith non-tubal
EPs and pretreatment hCGs as high as 48 558 IU/l by combiningminimal
doses ofmethotrexatewith a short courseof geﬁtinib. This co-treatment
approach can achieve better treatment outcomes with lower overall
drug exposure (Nilsson et al., 2013).
Another clinical factor negatively associated with methotrexate treat-
ment success is the presence of a fetal heart motion on ultrasound
(Bachman and Barnhart, 2012). In this case series of eight women, we
successfully treated two non-tubal EPs with embryonic cardiac activity,
including one participant who at repeat scanning on Day 4 of treatment,
showed the fetal heart motion to have already resolved. These cases
provide further encouraging preliminary evidence that this combination
treatment is efﬁcacious.
Themain goal of non-invasive treatment is preservation of reproduct-
ive potential. Importantly, all participants promptly resumed their men-
strual cycles after resolution of their non-tubal EPs with combination
geﬁtinib and methotrexate (within 6 weeks). Three participants have
subsequently conceived spontaneous intrauterine pregnancies, with
two women delivering a healthy infant at term (both normal vaginal
deliveries) and a third woman being in her second trimester of an
uncomplicated pregnancy.
Our continued experience with combination geﬁtinib and metho-
trexate treatment of women with ectopic pregnancies is that it
appears safe and well tolerated. There were no serious adverse events
recorded during the treatment of these eight women. Non-serious
adverse events, predominantly gastrointestinal and mucocutaneous,
were consistent with the known side effect proﬁles of both geﬁtinib
andmethotrexate. Furthermore, all side effectswere transient, requiring
only occasional symptomatic management and completely resolving
after discontinuation of treatment.
Treatment of non-small cell lung cancer with geﬁtinib is associated
with interstitial lung disease (ILD) in 1% of white and 5% of Japanese
patients, and is fatal in up to one-third of cases (Cataldo et al., 2011).
We have had no occurrences of ILD in any of our participants from
this andother studies, cumulatively 70women treatedwith ectopic preg-
nancies and persistent gestational trophoblastic disease from published
and unpublished data (Skubisz et al., 2013). We have screened for and
excludedwomenwith signiﬁcant pulmonary comorbidities and Japanese
ethnicity, and in addition to a short and limited 7-day course of geﬁtinib,
believe to risk of ILD in women of reproductive age to be unlikely.
In conclusion, we believe that combination geﬁtinib andmethotrexate
is a promising new treatment approach for non-tubal EPs. Whilst we
understand that it requires assessment of efﬁcacy in a large clinical trial
before it can be introduced into clinical practice, we believe that it has
the potential to reduce the need for surgical intervention, improve
future reproductive outcomes and minimize the burden of treatment
to both health services and women.
Supplementary data
Supplementarydata areavailable athttp://humrep.oxfordjournals.org/.
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